Adipotide - Generic Peptides

Buy Adipotide by Generic Peptides at XSteroids. Adipotide does not burn fat directly; it targets the blood vessels that feed white adipose tissue and cuts that supply. It produced the largest weight loss of any compound in this catalogue's fat-loss group when it was tested in obese rhesus monkeys, and it was then dropped because of kidney findings in the same study. Generic Peptides supplies it as lyophilized vials of 5 mg and 10 mg.

Two facts shape everything below. There are no published human efficacy results for adipotide, and there is no validated human dose. The vial is a research product for laboratory use.

What Adipotide Is and What You Are Buying

A single glass vial of white lyophilized powder makes up the order, filled at 5 mg or 10 mg with a stopper crimped in place. Nothing for mixing ships with it, so the diluent and the consumables have to be ordered on their own. The family listing covers both strengths, so the milligram figure is selected on the pack option rather than in the title.

Adipotide is also known as prohibitin-targeting peptide 1, abbreviated TP01. It is a peptide chimera built from two parts: a homing sequence, CKGGRAKDC, joined through a short glycine linker to a pro-apoptotic warhead, D(KLAKLAK)2. Its CAS number is 859216-15-2 and its PubChem record is 163360068. No human half-life has been established. What you are buying is therefore a laboratory reagent with a striking animal dataset and an unfinished clinical file, not a finished medicine.

How Adipotide Works Against Fat Vasculature

Homing to the blood supply of fat

The homing block recognises two proteins, ANXA2 and prohibitin, which are displayed on the endothelial cells lining the vessels of white adipose tissue. That recognition is the whole idea of the molecule: it does not aim at the fat cell, it aims at the plumbing that feeds it. Binding concentrates the peptide on those endothelial cells and leaves most other tissues comparatively untouched, which is why the approach is described as vascular targeting.

The warhead and the apoptosis step

Once the peptide is anchored, the KLAKLAK segment does the damage. It is taken into the cell, associates with mitochondria and disrupts them, pushing the endothelial cell into apoptosis. Without a working endothelium the fat depot loses its blood supply and shrinks, and in the animal model the loss was body-wide rather than limited to one site. This is the opposite logic to AOD 9604, which acts on the receptors inside the fat cell.

What distinguishes it from every other fat-loss peptide

Receptor agonists change the rate at which fat is released. Adipotide removes the tissue's support structure. That is a far more aggressive mechanism, and it explains both the size of the effect in monkeys and the reason the programme stopped: a molecule designed to kill endothelial cells can plausibly reach the kidney endothelium as well.

What to Expect from Adipotide in Research

The central study is a 2011 paper in Science Translational Medicine by Barnhart and colleagues. Obese rhesus macaques received the peptide for 28 days and lost roughly 10.6 percent of body weight, a figure no other peptide in this group approaches. The same work reported improved insulin sensitivity, with the treated animals needing about half the insulin they had needed before. Both findings were in monkeys, not in people.

The trial also found dose-dependent changes in the renal tubules, and that signal is the reason development was halted. The scientific foundation goes back further, to a 2004 Nature Medicine paper by Kolonin and colleagues in mice. Against that background, what a buyer should expect from the vial itself is honesty: there is no human body-composition data, no human safety dataset, and the Phase 1 study that was announced in the early 2010s never produced peer-reviewed results. Anyone looking for a documented human outcome will not find it here.

Dosing Adipotide in Research

Mixing the 5 mg and 10 mg vials

Decide the water volume first. Two millilitres in the 5 mg vial leave 2.5 mg/ml, which puts 250 mcg at the 10-unit line of a U-100 syringe; one millilitre raises it to 5 mg/ml and 500 mcg per 10 units. The 10 mg vial mirrors those figures with double the water: 4 ml leaves 2.5 mg/ml, which is 250 mcg at the 10-unit mark, and 2 ml doubles the strength to 5 mg/ml with 500 mcg at that mark. Swirl the vial instead of shaking it, and record the volume added.

Why there is no standard protocol

In the primate work the peptide was given intravenously once daily for 28 days, and that route and schedule do not translate into a sensible self-directed plan. Vendor notes describe 500 mcg to 1 mg per day subcutaneously as a convention, not as a validated protocol. For orientation only, a 5 mg vial at 500 mcg per day works out at about 10 days of material. Nothing on this page should be mistaken for a clinical regimen.

Stacking and Comparisons for Adipotide

In a research plan adipotide is usually compared rather than combined. AOD 9604 and HGH Frag 176-191 attack fat metabolism from the receptor side, while Somatropin is the full hormone and Tesamorelin is the releasing route with visceral fat data behind it. The appetite-driven options are Semaglutide, Tirzepatide and Retatrutide. No combination of adipotide with any of them has been studied, and adding a vascular-acting agent to a stack is not a neutral decision.

Recovery and Monitoring Around Adipotide

A conventional post-cycle therapy has nothing to do here, since adipotide does not suppress testosterone. The monitoring question is different and more serious. Because the documented adverse finding was renal, any serious research plan around this compound would track kidney markers such as creatinine and a urinalysis, and would set a stop rule in advance rather than after a symptom. Cycle length should follow the shortest period that answers the question being asked, and a break should be scheduled before the next vial is opened.

Adipotide Safety Concerns

The kidney signal

Dose-dependent renal tubular changes appeared in the same primate study that produced the weight loss, and they are the reason the development programme ended. No human safety data exist at all, so there is no way to know whether the animal finding translates, at what dose, or how quickly. Anyone with existing kidney disease should treat this compound as excluded on principle.

Regulatory position

Adipotide is not approved as a medicine anywhere, and clinical development has been discontinued. Because it is not a marketed drug there is no pharmacovigilance record, no label and no established maximum exposure.

Anti-doping status

No WADA Prohibited List entry carries adipotide, and the sport guidance documents do not deal with it separately. Missing data is the reason rather than an implied permission, and the peptide remains unapproved for human use.

Adipotide Handling and Storage Notes

The powder is held at 2 to 8 C with light excluded, and a freezer covers longer storage. Once liquid, the solution is kept at 2 to 8 C and used within 28 to 30 days; it is not frozen. Wipe the stopper before every draw, discard anything cloudy or carrying particles, and work from a single lot at a time so an observation can be traced to one vial.

Why Buy Research-Grade Adipotide from XSteroids?

XSteroids lists Generic Peptides Adipotide in 5 mg and 10 mg vials inside the Generic Peptides category, beside the other fat-loss research peptides. If the mechanism matters more than the headline number, read the AOD 9604 and HGH Frag 176-191 cards for the receptor-based approach, or Retatrutide for the multi-receptor route. Set the fill from the arithmetic above, then work through the mixed solution inside 30 days.